Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Cerebrospinal fluid biomarkers and cognitive performance in non-demented patients with Parkinson's disease.

Leverenz JB, Watson GS, Shofer J, Zabetian CP, Zhang J, Montine TJ.

Parkinsonism Relat Disord. 2011 Jan;17(1):61-4. doi: 10.1016/j.parkreldis.2010.10.003. Epub 2010 Nov 1.

2.

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

Alves G, Brønnick K, Aarsland D, Blennow K, Zetterberg H, Ballard C, Kurz MW, Andreasson U, Tysnes OB, Larsen JP, Mulugeta E.

J Neurol Neurosurg Psychiatry. 2010 Oct;81(10):1080-6. doi: 10.1136/jnnp.2009.199950. Epub 2010 Jun 14.

PMID:
20547614
3.

Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.

Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.

Parkinsonism Relat Disord. 2015 Jul;21(7):758-64. doi: 10.1016/j.parkreldis.2015.04.027. Epub 2015 May 2.

PMID:
25971633
4.

Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.

Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D.

J Parkinsons Dis. 2015;5(4):783-92. doi: 10.3233/JPD-150682.

5.

Cross-sectional and longitudinal associations of motor fluctuations and non-motor predominance with cerebrospinal τ and Aβ as well as dementia-risk in Parkinson's disease.

Modreanu R, Cerquera SC, Martí MJ, Ríos J, Sánchez-Gómez A, Cámara A, Fernández M, Compta Y.

J Neurol Sci. 2017 Feb 15;373:223-229. doi: 10.1016/j.jns.2016.12.064. Epub 2016 Dec 30.

PMID:
28131192
6.

Cerebrospinal fluid biomarkers and rate of cognitive decline in very mild dementia of the Alzheimer type.

Snider BJ, Fagan AM, Roe C, Shah AR, Grant EA, Xiong C, Morris JC, Holtzman DM.

Arch Neurol. 2009 May;66(5):638-45. doi: 10.1001/archneurol.2009.55.

7.

Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects.

Li G, Peskind ER, Millard SP, Chi P, Sokal I, Yu CE, Bekris LM, Raskind MA, Galasko DR, Montine TJ.

PLoS One. 2009;4(5):e5424. doi: 10.1371/journal.pone.0005424. Epub 2009 May 1.

8.

Grey matter volume correlates of cerebrospinal markers of Alzheimer-pathology in Parkinson's disease and related dementia.

Compta Y, Ibarretxe-Bilbao N, Pereira JB, Junqué C, Bargalló N, Tolosa E, Valldeoriola F, Muñoz E, Camara A, Buongiorno M, Martí MJ.

Parkinsonism Relat Disord. 2012 Sep;18(8):941-7. doi: 10.1016/j.parkreldis.2012.04.028. Epub 2012 May 15.

PMID:
22595621
9.

CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment.

Montine TJ, Shi M, Quinn JF, Peskind ER, Craft S, Ginghina C, Chung KA, Kim H, Galasko DR, Jankovic J, Zabetian CP, Leverenz JB, Zhang J.

Mov Disord. 2010 Nov 15;25(15):2682-5. doi: 10.1002/mds.23287.

10.

Amyloid-β and τ biomarkers in Parkinson's disease-dementia.

Buongiorno M, Compta Y, Martí MJ.

J Neurol Sci. 2011 Nov 15;310(1-2):25-30. doi: 10.1016/j.jns.2011.06.046. Epub 2011 Jul 20. Review.

PMID:
21764078
11.

CSF biomarkers associated with disease heterogeneity in early Parkinson's disease: the Parkinson's Progression Markers Initiative study.

Kang JH, Mollenhauer B, Coffey CS, Toledo JB, Weintraub D, Galasko DR, Irwin DJ, Van Deerlin V, Chen-Plotkin AS, Caspell-Garcia C, Waligórska T, Taylor P, Shah N, Pan S, Zero P, Frasier M, Marek K, Kieburtz K, Jennings D, Tanner CM, Simuni T, Singleton A, Toga AW, Chowdhury S, Trojanowski JQ, Shaw LM; Parkinson’s Progression Marker Initiative.

Acta Neuropathol. 2016 Jun;131(6):935-49. doi: 10.1007/s00401-016-1552-2. Epub 2016 Mar 28.

12.

Cerebrospinal fluid biomarkers and memory present distinct associations along the continuum from healthy subjects to AD patients.

Rami L, Fortea J, Bosch B, Solé-Padullés C, Lladó A, Iranzo A, Sánchez-Valle R, Molinuevo JL.

J Alzheimers Dis. 2011;23(2):319-26. doi: 10.3233/JAD-2010-101422.

PMID:
21098971
13.

Correlation between decreased CSF α-synuclein and Aβ₁₋₄₂ in Parkinson disease.

Buddhala C, Campbell MC, Perlmutter JS, Kotzbauer PT.

Neurobiol Aging. 2015 Jan;36(1):476-84. doi: 10.1016/j.neurobiolaging.2014.07.043. Epub 2014 Aug 4.

14.

Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease.

Körtvélyessy P, Gukasjan A, Sweeney-Reed CM, Heinze HJ, Thurner L, Bittner DM.

J Alzheimers Dis. 2015;46(2):375-80. doi: 10.3233/JAD-150069.

PMID:
25777512
15.

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.

Compta Y, Martí MJ, Ibarretxe-Bilbao N, Junqué C, Valldeoriola F, Muñoz E, Ezquerra M, Ríos J, Tolosa E.

Mov Disord. 2009 Nov 15;24(15):2203-10. doi: 10.1002/mds.22594.

PMID:
19795497
16.

Cross-sectional and longitudinal relationships between cerebrospinal fluid biomarkers and cognitive function in people without cognitive impairment from across the adult life span.

Li G, Millard SP, Peskind ER, Zhang J, Yu CE, Leverenz JB, Mayer C, Shofer JS, Raskind MA, Quinn JF, Galasko DR, Montine TJ.

JAMA Neurol. 2014 Jun;71(6):742-51. doi: 10.1001/jamaneurol.2014.445.

17.

CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report.

Gao R, Zhang G, Chen X, Yang A, Smith G, Wong DF, Zhou Y.

PLoS One. 2016 Oct 20;11(10):e0164762. doi: 10.1371/journal.pone.0164762. eCollection 2016.

18.

CSF biomarkers and clinical progression of Parkinson disease.

Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, Hansson O.

Neurology. 2015 Jan 6;84(1):57-63. doi: 10.1212/WNL.0000000000001098. Epub 2014 Nov 19.

19.

CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease.

Siderowf A, Xie SX, Hurtig H, Weintraub D, Duda J, Chen-Plotkin A, Shaw LM, Van Deerlin V, Trojanowski JQ, Clark C.

Neurology. 2010 Sep 21;75(12):1055-61. doi: 10.1212/WNL.0b013e3181f39a78. Epub 2010 Aug 18.

20.

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.

Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H, Blennow K, Forsgren L.

JAMA Neurol. 2015 Oct;72(10):1175-82. doi: 10.1001/jamaneurol.2015.1449.

PMID:
26258692

Supplemental Content

Support Center